|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-1-25
|
|
pubmed:abstractText |
Docetaxel is an effective agent for the treatment of androgen-independent prostate cancer (AIPC). Its combination with estramustine phosphate (EMP) has shown promising results in AIPC but the toxicity remains considerable. In an effort to minimize toxicity, we designed an every-2-week docetaxel administration regimen with a 3-day low-dose EMP regimen. Patients with bone metastases also received zoledronic acid.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Androgen Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal,
http://linkedlifedata.com/resource/pubmed/chemical/Diphosphonates,
http://linkedlifedata.com/resource/pubmed/chemical/Estramustine,
http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Prostate-Specific Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Taxoids,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/docetaxel,
http://linkedlifedata.com/resource/pubmed/chemical/zoledronic acid
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1527-9995
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
65
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
126-30
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:15667877-Adenocarcinoma,
pubmed-meshheading:15667877-Aged,
pubmed-meshheading:15667877-Aged, 80 and over,
pubmed-meshheading:15667877-Alopecia,
pubmed-meshheading:15667877-Androgen Antagonists,
pubmed-meshheading:15667877-Antineoplastic Agents, Hormonal,
pubmed-meshheading:15667877-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15667877-Bone Neoplasms,
pubmed-meshheading:15667877-Combined Modality Therapy,
pubmed-meshheading:15667877-Diphosphonates,
pubmed-meshheading:15667877-Disease Progression,
pubmed-meshheading:15667877-Disease-Free Survival,
pubmed-meshheading:15667877-Drug Resistance, Neoplasm,
pubmed-meshheading:15667877-Estramustine,
pubmed-meshheading:15667877-Humans,
pubmed-meshheading:15667877-Imidazoles,
pubmed-meshheading:15667877-Life Tables,
pubmed-meshheading:15667877-Liver Neoplasms,
pubmed-meshheading:15667877-Lung Neoplasms,
pubmed-meshheading:15667877-Lymphatic Metastasis,
pubmed-meshheading:15667877-Male,
pubmed-meshheading:15667877-Middle Aged,
pubmed-meshheading:15667877-Neoplasm Proteins,
pubmed-meshheading:15667877-Neutropenia,
pubmed-meshheading:15667877-Orchiectomy,
pubmed-meshheading:15667877-Pain,
pubmed-meshheading:15667877-Palliative Care,
pubmed-meshheading:15667877-Prostate-Specific Antigen,
pubmed-meshheading:15667877-Prostatic Neoplasms,
pubmed-meshheading:15667877-Radiotherapy, High-Energy,
pubmed-meshheading:15667877-Remission Induction,
pubmed-meshheading:15667877-Survival Analysis,
pubmed-meshheading:15667877-Taxoids,
pubmed-meshheading:15667877-Treatment Outcome,
pubmed-meshheading:15667877-Tumor Markers, Biological
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
|
|
pubmed:affiliation |
Department of Clinical Therapeutics, University of Athens School of Medicine, Haidari, Athens, Greece.
|
|
pubmed:publicationType |
Journal Article
|
